Additionally, treatment options like hormone therapy and monoclonal antibody therapy can enhance outcomes, based on the tumor’s cancer marker profile, particularly regarding hormone (estrogen and progesterone) receptor expression and the overexpression of the HER2 oncogene [3,4,5,6,7,8]. Here, ERBB2 is linked to neoplasm.